Pancreatic cancer has early but closely watched mRNA neoantigen vaccine research. Autogene cevumeran/BNT122/RO7198457 has been studied after surgery with atezolizumab and chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in pancreatic ductal adenocarcinoma. Larger studies are testing whether vaccine-induced immune responses can translate into fewer recurrences or longer control. Phase 3 work focuses heavily on the dominant KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → pathway. Daraxonrasib (RMC-6236), a pan-RAS inhibitor, is in Phase 3 in previously treated metastatic PDAC. BMS-986504 added to gemcitabine plus nab-paclitaxel is being compared against placebo in untreated metastatic disease. The Phase 2 APOLLO trial tests olaparib maintenance after curative-intent therapy in patients with resected PDAC and pathogenic BRCA1Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, BRCA2Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, or PALB2 mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →. Earlier work includes BNT327 (pumitamig), a PD-L1 and VEGF bispecific, with chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →; pegcetacoplan added to modified FOLFIRINOX; the MK2 inhibitor zunsemetinib with mFOLFIRINOX; and CA-4948 added to standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. Theranostic radioligand pairs targeting integrins and somatostatin receptors are in early study, and ASP2138 for claudin 18.2-positive disease is in Phase 1. Cachexia, a major source of decline, is being addressed in trials of ponsegromab and nano-megestrol acetate. Laboratory work is uncovering KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12D inhibitor resistance through Fra-2, KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12R-specific signaling vulnerabilities, immunosuppressive damage-associated macrophages targetable via GPR34, hypoxia-driven IL-6 from fibroblasts, and tumor-reactive T-cell repertoires that may inform future immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →.
Where the evidence stands
Combination chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → regimens remain the standard and have been incrementally improved over the last decade. PARP maintenance for BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation → carriers and immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → for the rare MMR-deficient subgroup are established. Pan-KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → and KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12D inhibitors are the most-watched late-stage developments. Most other novel approaches, including immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → combinations, ADCs, radioligands, and stromal-targeted strategies, are in Phase 1 or 2. Cachexia drugs are advancing in mid-stage trials. Most laboratory findings remain years from the clinic.
What this means for people affected
Pancreatic cancer remains a field where standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → is the foundation and new treatments have not yet substantially shifted survival for most people. The exceptions are biomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation →-defined subgroups: BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, PALB2, MSI-high, NTRK or NRG1 fusion, and KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C. Comprehensive molecular profiling, including germline testing, is reasonable at diagnosis of advanced disease because it occasionally identifies these treatable groups. The recent KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →-directed Phase 3 programs are the most consequential trials in the field, and clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → enrollment is recommended in many guidelines because standard options remain limited. Supportive care for cachexia, pain, and symptom burden is an active research area and a meaningful part of treatment.
Last updated May 22, 2026
Recent research findings
Understanding evidence levels▼
PreclínicoLab or cell studies — no human data yet.
Estudio en animalesResults in animals only — may not apply to humans.
Ensayo Fase 1First-in-human safety testing in small groups.
Ensayo Fase 2Early effectiveness testing in a larger group.
Ensayo Fase 3Large controlled trial — the strongest trial evidence.
Estudio observacionalPatterns observed in populations — not a controlled trial.
RevisiónSummary analysis of multiple existing studies.
MetaanálisisStatistical pooling of results from multiple studies.
Estudio observacionalPatrones observados en poblaciones a lo largo del tiempo, no es un experimento controlado.Published: May 22, 2026
Comparing Two Biopsy Techniques for Pancreatic Lesions
Researchers compared two methods for diagnosing pancreatic lesions: ultrasound-guided core needle biopsies and endoscopic ultrasound-guided fine-needle aspirations. They found that the first method was more accurate in most cases, especially for smaller lesions. However, more research is needed to confirm these findings.
Why it matters: This study's findings may help doctors choose the best biopsy technique for patients with pancreatic lesions.
Efficacy
US-CNB demonstrated higher diagnostic efficiency, with efficiencies of 96.4% and 70.8% for the US-CNB and EUS-FNA groups, respectively.
Estudio de laboratorioExperimentos de laboratorio en células o tejidos. Sin datos humanos ni animales.Published: May 22, 2026
Understanding the Role of B-Cells in Pancreatic Cancer
Researchers studied how B-cells contribute to pancreatic cancer development and found that their role is complex and often contradictory. They found that B-cells can both suppress and enhance anti-tumor immune responses. The exact mechanisms are still being explored.
Why it matters: This finding may help explain why some treatments targeting B-cells have failed in clinical trialsA research study that tests a medical intervention in human volunteers.Click for full explanation → and could lead to new approaches for treating pancreatic cancer.
The study's findings are based on lab experiments and may not directly apply to human patients.
Estudio observacionalPatrones observados en poblaciones a lo largo del tiempo, no es un experimento controlado.Published: May 22, 2026
ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →'s Impact on Pancreatic Cancer Patients' Mortality
Researchers analyzed data from over 9,600 pancreatic cancer patients who received chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → to understand how modern treatment affects their mortality rates. They found that non-cancer deaths, such as heart disease and infections, are a significant concern, especially in the first year after diagnosis. The study suggests that these deaths are related to the treatment itself.
Why it matters: This finding highlights the need for integrated care approaches that address the physical and psychological effects of chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in pancreatic cancer patients.
Estudio de laboratorioExperimentos de laboratorio en células o tejidos. Sin datos humanos ni animales.Published: May 21, 2026
Amplified genes near F3 linked to poor outcomes in pancreatic cancer
Researchers studied how genes near the F3 gene are amplified in pancreatic cancer. They found that patients with more amplified genes had worse survival rates. The study suggests that this amplification might contribute to the cancer's growth and blood clotting.
Why it matters: This finding could help scientists understand how pancreatic cancer progresses and identify new targets for treatment.
Estudio observacionalPatrones observados en poblaciones a lo largo del tiempo, no es un experimento controlado.Published: May 21, 2026
Pancreatic Cancer Patients' Quality of Life Before Surgery May Predict Outcomes
Researchers studied how quality of life affects pancreatic cancer patients before surgery. They found that patients with lower quality of life scores had a higher risk of cancer recurrence and lower survival rates, but the relationship was weak. The study involved 112 patients with pancreatic or periampullary cancer.
Why it matters: This finding may help doctors identify patients who are at higher risk of poor outcomes after surgery, allowing for more personalized care.
Ensayo Fase 2Evalúa la eficacia inicial en un grupo más amplio después de establecer la seguridad en la fase 1.Est. completion: August 14, 2028
Testing Radiotherapy and Maintenance Therapy for Advanced Pancreatic Cancer
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the effectiveness of combining stereotactic body radiotherapy (SBRT) with maintenance therapy for patients with advanced pancreatic cancer that cannot be removed surgically. The trial is currently recruiting participants. The results of this study will help determine if this combination of treatments is beneficial for patients with this type of cancer.
Why it matters: This trial may help improve treatment options for people with advanced pancreatic cancer.
Estudio de laboratorioExperimentos de laboratorio en células o tejidos. Sin datos humanos ni animales.Published: May 19, 2026
UBE2C linked to pancreatic cancer progression
Researchers studied how a protein called UBE2C affects pancreatic cancer cells in lab experiments. They found that UBE2C is overexpressed in pancreatic cancer cells and tissues, and that this might contribute to the cancer's growth and spread. However, more research is needed to confirm these findings.
Why it matters: This study suggests that UBE2C could be a potential biomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → for pancreatic cancer and a target for future treatments.
Lab experiments were conducted on pancreatic cancer cell lines and tissues.
PreclínicoEstudios de laboratorio o celulares. Sin datos humanos aún.Est. completion: May 1, 2028
Preparing Sarcopenic Patients for Pancreatic Cancer Surgery
This trial is studying whether a prehabilitation program can help patients with sarcopenia and pancreatic cancer prepare for surgery. The program includes a preoperative prehabilitation program and oral nutrition. The trial is currently recruiting participants.
Why it matters: This trial aims to improve outcomes for patients with pancreatic cancer and sarcopenia by optimizing their physical condition before surgery.
Ensayo Fase 1Primer ensayo en humanos. Se centra en la seguridad y dosificación en grupos pequeños.Est. completion: December 31, 2028
Exploring New Treatment Combinations for Advanced Gastrointestinal Cancers
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the combination of two treatments, Pelareorep and Atezolizumab, for patients with advanced or metastatic gastrointestinal cancers. The trial is currently active but not recruiting participants. The goal is to understand the safety and effectiveness of this treatment combination.
Why it matters: This trial may help identify new treatment options for patients with advanced gastrointestinal cancers.
PreclínicoEstudios de laboratorio o celulares. Sin datos humanos aún.Est. completion: December 31, 2026
Exercise and Nutrition Study for Pancreatic Cancer Patients
This trial is studying how a combination of exercise and nutrition counseling affects pancreatic cancer patients during preoperative therapy. The trial is currently active but not recruiting participants. The goal is to understand the potential benefits of this approach.
Why it matters: This trial may help improve the quality of life for pancreatic cancer patients undergoing preoperative therapy.
Active but not recruiting participants; exact phase not specified
Ensayo Fase 1Primer ensayo en humanos. Se centra en la seguridad y dosificación en grupos pequeños.Est. completion: June 30, 2030
Testing XH001 Injection as Adjuvant Therapy for High-risk Recurrent Solid Tumors
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the safety and effectiveness of XH001 Injection as a treatment for patients with high-risk recurrent solid tumors, such as biliary cancer, pancreatic cancer, and liver cancer. The trial is currently recruiting participants. The results of this trial are not yet available.
Why it matters: This trial may help doctors understand if XH001 Injection can be a useful treatment option for patients with high-risk recurrent solid tumors.
Ensayo Fase 1Primer ensayo en humanos. Se centra en la seguridad y dosificación en grupos pequeños.Est. completion: February 1, 2029
Testing DA 3501 in Advanced Stomach and Pancreatic Cancer
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a new treatment called DA 3501 in patients with advanced stomach or pancreatic cancer. The trial is currently recruiting participants. The goal is to evaluate the safety and effectiveness of DA 3501 in these patients.
Why it matters: This trial may help determine if DA 3501 is a safe and effective treatment option for patients with advanced stomach or pancreatic cancer.
Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
